TGF-β Inhibition and Immunotherapy: Checkmate

Karuna Ganesh; Joan Massagué

doi:10.1016/j.immuni.2018.03.037

TGF-β Inhibition and Immunotherapy: Checkmate

Immunity. 2018 Apr 17;48(4):626-628. doi: 10.1016/j.immuni.2018.03.037.

Authors

Karuna Ganesh¹, Joan Massagué²

Affiliations

¹ Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA; Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
² Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: massaguj@mskcc.org.

Abstract

Immune checkpoint therapy can induce durable remissions, but many tumors demonstrate resistance. In a recent issue of Nature, Mariathasan et al. (2018) and Tauriello et al. (2018) identify stromal TGF-β signaling as a determinant of immune exclusion. Combination TGF-β inhibition and immunotherapy induces complete responses in mouse models.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Disease Models, Animal
Immunotherapy
Mice
Neoplasms
T-Lymphocytes*
Transforming Growth Factor beta*

Substances

Transforming Growth Factor beta

Abstract

Publication types

MeSH terms

Substances

Grants and funding